Baseline patient characteristics
| Characteristic . | Number of patients, n = 39 (%) . |
|---|---|
| Age (y), median (range) | 62 (25-77) |
| Female | 21 (53.8) |
| Median time from HCT to study entry (range), mo | 43 (6-173) |
| ECOG performance status | |
| 0 | 1 (2.6) |
| 1 | 27 (69.2) |
| 2 | 11 (28.2) |
| Indication for transplant | |
| AML | 18 (46.2) |
| MDS | 8 (20.5) |
| ALL | 5 (12.8) |
| CML | 2 (5.1) |
| MPD | 2 (5.1) |
| MPN with fibrosis | 2 (5.1) |
| Myelofibrosis | 1 (2.6) |
| NHL | 1 (2.6) |
| Stem cell source | |
| Bone marrow | 4 (10.3) |
| Peripheral blood stem cell | 35 (89.7) |
| Conditioning intensity | |
| Myeloablative | 24 (61.5) |
| Nonmyeloablative | 14 (35.9) |
| Unknown | 1 (2.6) |
| HLA matching (A, B, C, and DRB1) | |
| Matched related | 15 (38.4) |
| Matched unrelated | 22 (56.4) |
| Mismatched related | 1 (2.6) |
| Mismatched unrelated | 1 (2.6) |
| Baseline NIH cGVHD severity score | |
| Mild | 0 (0) |
| Moderate | 18 (46.2) |
| Severe | 21 (53.8) |
| Organs involved | |
| Number of organs involved, median (range) | 3 (2-7) |
| ≥4 organs involved | 19 (48.7) |
| Skin | 33 (84.6) |
| Mouth | 17 (43.5) |
| Eyes | 28 (71.7) |
| GI | 6 (15.3) |
| Liver | 9 (23.1) |
| Lung | 22 (56.4) |
| Joints | 32 (82.1) |
| Prior systemic therapy for cGVHD | |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Corticosteroid (prednisone, methylprednisolone) | 39 (100) |
| Tacrolimus | 24 (61.5) |
| Mycophenolate mofetil | 15 (38.5) |
| Sirolimus | 11 (28.2) |
| Cyclosporine | 2 (5.1) |
| Rituximab | 10 (25.6) |
| Ruxolitinib | 7 (17.9) |
| Ibrutinib | 4 (10.3) |
| Aldesleukin | 7 (17.9) |
| Characteristic . | Number of patients, n = 39 (%) . |
|---|---|
| Age (y), median (range) | 62 (25-77) |
| Female | 21 (53.8) |
| Median time from HCT to study entry (range), mo | 43 (6-173) |
| ECOG performance status | |
| 0 | 1 (2.6) |
| 1 | 27 (69.2) |
| 2 | 11 (28.2) |
| Indication for transplant | |
| AML | 18 (46.2) |
| MDS | 8 (20.5) |
| ALL | 5 (12.8) |
| CML | 2 (5.1) |
| MPD | 2 (5.1) |
| MPN with fibrosis | 2 (5.1) |
| Myelofibrosis | 1 (2.6) |
| NHL | 1 (2.6) |
| Stem cell source | |
| Bone marrow | 4 (10.3) |
| Peripheral blood stem cell | 35 (89.7) |
| Conditioning intensity | |
| Myeloablative | 24 (61.5) |
| Nonmyeloablative | 14 (35.9) |
| Unknown | 1 (2.6) |
| HLA matching (A, B, C, and DRB1) | |
| Matched related | 15 (38.4) |
| Matched unrelated | 22 (56.4) |
| Mismatched related | 1 (2.6) |
| Mismatched unrelated | 1 (2.6) |
| Baseline NIH cGVHD severity score | |
| Mild | 0 (0) |
| Moderate | 18 (46.2) |
| Severe | 21 (53.8) |
| Organs involved | |
| Number of organs involved, median (range) | 3 (2-7) |
| ≥4 organs involved | 19 (48.7) |
| Skin | 33 (84.6) |
| Mouth | 17 (43.5) |
| Eyes | 28 (71.7) |
| GI | 6 (15.3) |
| Liver | 9 (23.1) |
| Lung | 22 (56.4) |
| Joints | 32 (82.1) |
| Prior systemic therapy for cGVHD | |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Corticosteroid (prednisone, methylprednisolone) | 39 (100) |
| Tacrolimus | 24 (61.5) |
| Mycophenolate mofetil | 15 (38.5) |
| Sirolimus | 11 (28.2) |
| Cyclosporine | 2 (5.1) |
| Rituximab | 10 (25.6) |
| Ruxolitinib | 7 (17.9) |
| Ibrutinib | 4 (10.3) |
| Aldesleukin | 7 (17.9) |
Baseline patient characteristics of the 39 patients enrolled in the trial including key transplant, cGVHD, and immunosuppressant management features.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplant; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.